Defining and targeting adaptations to oncogenic KRASG12C inhibition using quantitative temporal proteomics
N. Santana-Codina, A. S. Chandhoke, Q. Yu, B. Małachowska, M. Kuljanin, A. Gikandi, M. Stanczak, S. Gableske, M. P. Jedrychowski, D. A. Scott, A. J. Aguirre, W. Fendler, N. S. Gray, J. D. Mancias
This study uses quantitative temporal proteomics to analyze KRASG12C inhibitor responses in cancer models, identifying effective drug combinations to overcome resistance.
bioRxiv · Sep 14, 2019Cancer Biology